Eris Gets CDSCO Panel Nod To Dapagliflozin-Bisoprolol-Sacubitril Valsartan Combo Kit, Phase IV Trial Mandated
New Delhi: The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has approved the manufacturing and marketing application submitted by Eris Lifesciences Limited for its Combi-Kit of Dapagliflozin + Bisoprolol + Sacubitril and Valsartan, with the condition to conduct a Phase IV clinical trial.
The proposal was reviewed during the SEC Cardiovascular meeting held on 10th July 2025 at CDSCO headquarters, New Delhi.
Eris Lifesciences presented its application along with a justification for a bioequivalence (BE) study waiver and a Phase III clinical trial (CT) waiver before the committee. The proposed Combi-Kit includes combinations of:
Dapagliflozin Propanediol equivalent to Dapagliflozin 10 mg (multiple doses)
Bisoprolol Fumarate IP 1.25 mg/2.5 mg/5 mg/10 mg
Sacubitril and Valsartan IP in strengths of 50 mg (24 mg and 26 mg), 100 mg (49 mg and 51 mg), and 200 mg (97 mg and 103 mg)
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.